The patented SHYCOCAN® technology that powers Serenio was first developed in India in 2017 by Group Chairman of Organization de Scalene, Director and Chief Scientific officer of the Centre for Advanced Research and Development (CARD), Director of Scalene Energy Research Institute (SERI) and Managing Director of Scalene Cybernetics limited, Rajah Vijay Kumar D.Sc. Tired of his employees missing work due to viral illness, he developed the groundbreaking device to disable viruses in real-world environments before they infect others. Since then, extensive testing has shown that the device is capable of 95% neutralization of the SARS-CoV-2 virus and effective destruction of the Influenza B virus and the avian SARS-CoV virus, also known as “bird flu,” in the air and on surfaces. Learn more about the technology that powers Serenio.
When the global pandemic began, Dr. William Kedia, MD witnessed firsthand the suffering caused by COVID-19 not only in his patients in the US, but also in close family members around the globe. When he heard about a one-of-a-kind device capable of neutralizing coronavirus in the air, he recognized the impact this innovative technology could have on the global community and sought a way to bring it to the U.S.
Dr. Kedia, along with co-founders Murthy Talasila and Sonny Verma, partnered with Shreis Scalene Therapeutics in 2020 to bring the Shycocan technology to the U.S. market, and thus MedAir Labs was born. MedAir Labs, based in Solon, Ohio, is dedicated to developing solutions to assist in the global health crisis and has invested significant resources into manufacturing, marketing and distributing Serenio, which is based on the Shycocan technology, in the U.S.
Through his work with MedAir Labs, Dr. Kedia aims to make all spaces where people congregate safer. From medical industry venues like operating and procedure rooms, to communal living spaces like nursing and group homes, to schools, theaters, offices, restaurants, gyms and even residential homes, Serenio delivers peace of mind.